Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19672580 | 0.78 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1 | |
| SCHEMBL14549411 | 0.74 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1 | |
| SCHEMBL92781 | 0.71 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1 | |
| SCHEMBL19756630 | 0.70 | NOX1 (0.41) | TP53NOX1TLR8TLR7PRKD1 | |
| SCHEMBL31448167 | 0.70 | ALDH1A1 (0.41) | SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1 | |
| Bromide SCHEMBL10996884 | 0.70 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1 | |
| SCHEMBL31201851 | 0.69 | HSD17B10 (0.56) | SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1 | |
| SCHEMBL28601366 | 0.69 | ALDH1A1 (0.49) | SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1 | |
| SCHEMBL991889 | 0.68 | ALDH1A1 (0.57) | SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1 | |
| SCHEMBL1319670 | 0.68 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106456615-B | Antiviral compounds, pharmaceutical compositions and methods of use thereof | 奇尼塔公司 | 2020-10-27 | — | — | CN | disclosed |
| US-20200270274-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2020-08-27 | — | — | US | disclosed |
| US-20200270274-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2020-08-27 | — | — | US | disclosed |
| US-20190002477-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2019-01-03 | — | — | US | disclosed |
| US-20190002477-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2019-01-03 | — | — | US | disclosed |
| US-9884876-B2 | Anti-viral compounds, pharmaceutical compositions, and methods of use thereof | Kineta, Inc. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884876-B2 | Anti-viral compounds, pharmaceutical compositions, and methods of use thereof | Kineta, Inc. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884876-B2 | Anti-viral compounds, pharmaceutical compositions, and methods of use thereof | Kineta, Inc. (US) | 2018-02-06 | — | — | US | disclosed |
| EP-3139920-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20170057978-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170057978-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170057978-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2017-03-02 | — | — | US | disclosed |
| EP-2945625-A2 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2015-11-25 | — | — | EP | disclosed |
| WO-2015172099-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2015-11-12 | — | — | WO | disclosed |
| WO-2014113492-A2 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014113492-A2 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2014-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057978-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MAVS, IRF3, EIF2AK2 | SMN1; SMN2 1742/4885NPC1 571/4885RAB9A 923/4885 |
| US-20200270274-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MAVS, IRF3, EIF2AK2 | SMN1; SMN2 1742/4885NPC1 571/4885RAB9A 923/4885 |
| US-20190002477-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MAVS, IRF3, EIF2AK2 | SMN1; SMN2 1742/4885NPC1 571/4885RAB9A 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.